Design and rationale of the PREVENT III Clinical trial: Edifoligide for the prevention of infrainguinal vein graft failureCONTE, Michael S; LORENZ, Todd J; BANDYK, Dennis F et al.Vascular and endovascular surgery. 2005, Vol 39, Num 1, pp 15-23, issn 1538-5744, 9 p.Article

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)HERNANDEZ, Adrian F; O'CONNOR, Christopher M; MASSIE, Barry et al.The American heart journal. 2009, Vol 157, Num 2, pp 271-277, issn 0002-8703, 7 p.Article

Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgeryHALABI, Abdul R; ALEXANDER, John H; SHAW, Linda K et al.The American journal of cardiology. 2005, Vol 96, Num 9, pp 1254-1259, issn 0002-9149, 6 p.Article

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary interventionGILCHRIST, Ian C; O'SHEA, J. Conor; RUNYON, John et al.Circulation (New York, N.Y.). 2001, Vol 104, Num 4, pp 406-411, issn 0009-7322Article

Design and methodology of the ESPRIT trial : Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionO'SHEA, J. Conor; MADAN, Mina; CANTOR, Warren J et al.The American heart journal. 2000, Vol 140, Num 6, pp 834-839, issn 0002-8703Article

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year resultsLOPES, Renato D; WILLIAMS, Judson B; CALIFF, Robert M et al.The American heart journal. 2012, Vol 164, Num 3, pp 379-386, issn 0002-8703, 8 p.Article

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide : Results from PURSUIT. DiscussionDYKE, Cornelius M; BHATIA, Devinder; BEHOLZ, Sven et al.The Annals of thoracic surgery. 2000, Vol 70, Num 3, pp 866-872, issn 0003-4975Conference Paper

The PRoject of ex-vivo vein graft ENgineering via transfection IV (PREVENT IV) trial : Study rationale, design, and baseline patient characteristicsALEXANDER, John H; FERGUSON, T. Bruce; LEE, Kerry L et al.The American heart journal. 2005, Vol 150, Num 4, pp 643-649, issn 0002-8703, 7 p.Article

Relationship of creatine kinase-myocardial bond release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudyGIBSON, C. Michael; MURPHY, Sabina A; MARBLE, Susan J et al.The American heart journal. 2002, Vol 143, Num 1, pp 106-110, issn 0002-8703Article

Clinical pharmacology of higher dose Eptifibatide in percutaneous coronary intervention (The PRIDE Study)TCHENG, James E; TALLEY, J. David; KITT, Michael M et al.The American journal of cardiology. 2001, Vol 88, Num 10, pp 1097-1102, issn 0002-9149Article

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. CommentaryCONTE, Michael S; BANDYK, Dennis F; BERCELI, Scott A et al.Journal of vascular surgery. 2006, Vol 43, Num 4, pp 742-751, issn 0741-5214, 10 p.Conference Paper

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT studyFERNANDES, Laura S; TCHENG, James E; MANN, Tift et al.Journal of the American College of Cardiology. 2002, Vol 40, Num 6, pp 1085-1091, issn 0735-1097Article

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention : The ESPRIT trial : A randomized controlled trialO'SHEA, J. Conor; HAFLEY, Cail E; GREENBERG, Sally et al.JAMA, the journal of the American Medical Association. 2001, Vol 285, Num 19, pp 2468-2473, issn 0098-7484Article